利妥昔单抗再诱导缓解后复发的ANCA相关血管炎患者的复发危险因素
该研究为RITAZAREM试验的事后分析,纳入170例经利妥昔单抗再诱导缓解的AAV患者,随机接受维持治疗至24个月后观察至48个月。维持期肌肉骨骼受累和患者整体评估较高与复发相关;停药期CD19+ B细胞存在和ANCA再现与复发风险升高相关。
要点
- 维持期肌肉骨骼受累与复发风险升高相关(OR 2.8)。
- 停药期CD19+ B细胞存在与复发风险升高相关(OR 2.5)。
- 停药期ANCA再现与复发风险升高相关(OR 3.2)。
核心结论
- AAV复发危险因素因治疗阶段而异,监测炎症标志物和免疫重建可能识别复发高危患者,尤其在停药后。
研究设计与样本
- RITAZAREM临床试验的事后分析,纳入170例15岁及以上、抗PR3或抗MPO-ANCA阳性且经利妥昔单抗再诱导缓解的AAV患者,随机接受利妥昔单抗或硫唑嘌呤维持治疗至24个月,随后观察至复发或48个月。
主要发现
- 共发生99次复发,其中46次发生于维持期。
- 维持期肌肉骨骼受累(OR 2.8,95%CI 1.1-7.2,P=0.03)和患者整体评估较高(OR 1.1,95%CI 1.0-1.2,P=0.04)与复发相关。
- 停药期CD19+ B细胞存在(OR 2.5,95%CI 1.2-5.1,P=0.01)和ANCA再现(OR 3.2,95%CI 1.3-7.7,P=0.01)与复发风险升高相关。
- 多变量分析识别出炎症标志物(血小板、白细胞和IgA的变化)与复发相关。
临床怎么用
- 在维持期关注肌肉骨骼受累和患者整体评估,停药期监测CD19+ B细胞和ANCA,可能有助于识别复发高危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of the study was to determine risk factors for relapse of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) after reinduction of remission with rituximab and discontinuation of maintenance therapy. METHODS: This is a post hoc analysis of the RITAZAREM clinical trial. Patients aged 15 years or older with AAV and a positive test for anti-proteinase-3 or anti-myeloperoxidase-ANCA who achieved remission after reinduction with rituximab and glucocorticoids were randomized at month 4 to receive continued rituximab or azathioprine for a maintenance period up to 24 months, followed by observation until relapse or up to 48 months. Generalized estimating equations logistic regression identified baseline and time-varying risk factors for relapse by the next visit for the two study phases: maintenance (months 4-24) and off-treatment (months 24-48). RESULTS: Among 170 patients (median [interquartile range] age 59 [48-68] years, disease duration 5 [2-10] years), 99 relapses occurred (46 during maintenance). During maintenance, musculoskeletal involvement (odds ratio [OR]: 2.8, 95% confidence interval [CI]: 1.1-7.2; P = 0.03) and higher patient global assessment (OR: 1.1, 95% CI: 1.0-1.2; P = 0.04) were associated with relapse. During the off-treatment phase, presence of CD19+ B cells (OR: 2.5, 95% CI: 1.2-5.1; P = 0.01) and reappearance of ANCA (OR: 3.2, 95% CI: 1.3-7.7; P = 0.01) were each associated with higher relapse risk. Multivariable analysis identified markers of inflammation (changes in platelets, white blood cells, and IgA) associated with relapse. CONCLUSION: Risk factors for relapse in AAV vary by treatment phase. Monitoring markers of inflammation and immune reconstitution may identify patients at risk for relapse, particularly after treatment withdrawal.
引用
- Romich E, Baker JF, Riley TR, et al. Risk Factors for Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Among Patients With Relapse After Induction of Remission With Rituximab. Arthritis Rheumatol. 2026. PMID: 41412975. doi:10.1002/art.70025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。